Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Total Valuation
Legend Biotech has a market cap or net worth of $3.47B. The enterprise value is $1.24B.
Market Cap$3.47B
Enterprise Value$1.24B
Share Statistics
Legend Biotech has 184,955,640 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding184,955,640
Owned by Insiders―
Owned by Institutions5.94%
Financial Efficiency
Legend Biotech’s return on equity (ROE) is -0.30 and return on invested capital (ROIC) is -9.61%.
Return on Equity (ROE)-0.30
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-9.61%
Return on Capital Employed (ROCE)-0.12
Revenue Per Employee396.78K
Profits Per Employee-114.46K
Employee Count2,600
Asset Turnover0.60
Inventory Turnover12.79
Valuation Ratios
The current PE Ratio of Legend Biotech is ―. Legend Biotech’s PEG ratio is -0.10.
PE Ratio―
PS Ratio1.94
PB Ratio2.00
Price to Fair Value2.00
Price to FCF-11.92
Price to Operating Cash Flow-8.94
PEG Ratio-0.10
Income Statement
In the last 12 months, Legend Biotech had revenue of 1.03B and earned -297.58M in profits. Earnings per share was -3.22.
Revenue1.03B
Gross Profit622.44M
Operating Income-136.86M
Pretax Income-283.35M
Net Income-297.58M
EBITDA-107.78M
Earnings Per Share (EPS)-3.22
Cash Flow
In the last 12 months, operating cash flow was -193.64M and capital expenditures -37.15M, giving a free cash flow of -230.79M billion.
Operating Cash Flow-193.64M
Free Cash Flow-230.79M
Free Cash Flow per Share-1.25
Dividends & Yields
Legend Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.60
52-Week Price Change-50.58%
50-Day Moving Average19.44
200-Day Moving Average29.58
Relative Strength Index (RSI)48.26
Average Volume (3m)2.06M
Important Dates
Legend Biotech upcoming earnings date is May 19, 2026, After Close (Confirmed).
Last Earnings DateMar 10, 2026
Next Earnings DateMay 19, 2026
Ex-Dividend Date―
Financial Position
Legend Biotech as a current ratio of 1.96, with Debt / Equity ratio of 41.28%
Current Ratio1.96
Quick Ratio1.91
Debt to Market Cap0.16
Net Debt to EBITDA4.53
Interest Coverage Ratio-6.38
Taxes
In the past 12 months, Legend Biotech has paid 14.24M in taxes.
Income Tax14.24M
Effective Tax Rate-0.05
Enterprise Valuation
Legend Biotech EV to EBITDA ratio is -14.06, with an EV/FCF ratio of -9.02.
EV to Sales1.47
EV to EBITDA-14.06
EV to Free Cash Flow-9.02
EV to Operating Cash Flow-15.08
Balance Sheet
Legend Biotech has $948.60M in cash and marketable securities with $413.70M in debt, giving a net cash position of $534.90M billion.
Cash & Marketable Securities$948.60M
Total Debt$413.70M
Net Cash$534.90M
Net Cash Per Share$2.89
Tangible Book Value Per Share$10.94
Margins
Gross margin is 60.33%, with operating margin of -13.27%, and net profit margin of -28.85%.
Gross Margin60.33%
Operating Margin-13.27%
Pretax Margin-27.47%
Net Profit Margin-28.85%
EBITDA Margin-10.45%
EBIT Margin-13.27%
Analyst Forecast
The average price target for Legend Biotech is $56.19, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$56.19
Price Target Upside199.68% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast74.91%
EPS Growth Forecast31.54%